Acute Kidney Injury (AKI) — Diagnosis and Management
Diagnose AKI using KDIGO criteria: serum creatinine rise ≥0.3 mg/dL within 48 hours, ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/hr for 6 hours. Immediate management centers on volume resuscitation with balanced crystalloids (Lactated Ringer or Plasmalyte) at 1–2 mL/kg/hr, discontinuation of all nephrotoxins (NSAIDs, aminoglycosides, iodinated contrast), and hemodynamic optimization targeting MAP ≥65 mmHg. Initiate renal replacement therapy for life-threatening hyperkalemia (K+ >6.5 mEq/L with ECG changes), refractory pulmonary edema, severe acidosis (pH <7.1), or uremic complications. Monitor creatinine trends every 6–12 hours, urine output hourly, and electrolytes every 4–6 hours in the acute phase.
🧪 eGFR & CKD Stage
CKD-EPI 2021 equation. Enter serum creatinine, age, sex.
≥90
60–89
30–59
15–29
<15
Pathophysiology
Acute kidney injury represents a sudden decline in glomerular filtration rate caused by ischemic, nephrotoxic, or obstructive insults that disrupt the tightly regulated balance between renal oxygen delivery and tubular oxygen consumption. The kidney receives 20–25% of cardiac output but distributes blood unevenly—the outer medulla operates at a baseline PaO2 of only 10–20 mmHg, making the S3 segment of the proximal tubule and the thick ascending limb of the loop of Henle exquisitely vulnerable to hypoperfusion.
- Core Mechanism
- Tubular epithelial cell injury from ischemia-reperfusion or direct nephrotoxin exposure, leading to loss of brush border integrity, cell detachment, and intraluminal cast formation that obstructs flow
- Key Pathway
- ATP depletion → cytoskeletal disruption → loss of cell polarity → Na+/K+-ATPase redistribution to apical membrane → tubuloglomerular feedback activation → afferent arteriolar vasoconstriction → GFR drop
- Genetic Factors
- APOL1 G1/G2 variants (3–4× AKI risk in African ancestry), polymorphisms in ACE, IL-6, and TNF-alpha genes modulate susceptibility; HLA-DRB1 alleles linked to drug-induced interstitial nephritis
- Risk Factors
- MODIFIABLE: nephrotoxin exposure (NSAIDs, aminoglycosides, contrast), volume depletion, hypotension | NON-MODIFIABLE: age >65, pre-existing CKD (eGFR <60), diabetes, heart failure, sepsis
- Biomarkers
- Serum creatinine (lags 24–48h behind injury), cystatin C (less muscle-mass dependent), NGAL (rises within 2h of injury, >150 ng/mL predicts AKI), KIM-1, TIMP-2 × IGFBP7 (NephroCheck ≥0.3 = high risk)
The pathophysiologic cascade begins with a hemodynamic or toxic insult that depletes intracellular ATP in tubular epithelial cells within minutes. Without ATP, the Na+/K+-ATPase pump fails, causing sodium to accumulate intracellularly and water to follow, producing cellular swelling. Simultaneously, calcium floods the cytoplasm through voltage-gated channels, activating phospholipases and proteases that degrade the cytoskeleton and cell membrane. Injured tubular cells lose polarity and detach from the basement membrane, forming obstructive casts with Tamm-Horsfall protein in the tubular lumen. These casts increase intratubular pressure, reducing the net filtration pressure across the glomerulus. In parallel, damaged tubular cells release damage-associated molecular patterns (DAMPs) that activate toll-like receptors on resident dendritic cells and macrophages, triggering a sterile inflammatory response. Neutrophil infiltration amplifies tissue damage through reactive oxygen species and proteolytic enzymes. The macula densa senses increased chloride delivery from dysfunctional upstream tubules and activates tubuloglomerular feedback, causing afferent arteriolar vasoconstriction that further reduces GFR. Endothelial injury in peritubular capillaries causes microvascular congestion, leukocyte adhesion, and extension of the outer medullary ischemic zone. Recovery depends on surviving tubular cells dedifferentiating, proliferating, and re-establishing a polarized monolayer—a process that takes days to weeks and may remain incomplete, leaving residual interstitial fibrosis that predisposes to CKD progression.
Diagnostic Protocol
Suspect AKI in any hospitalized patient with rising creatinine, declining urine output, or worsening volume status. The diagnostic approach begins with establishing baseline creatinine (use the lowest value in the prior 3 months, or estimate from the MDRD equation if unavailable), classifying the AKI stage, then systematically differentiating prerenal, intrinsic, and postrenal etiologies. A focused history should assess recent nephrotoxin exposure (NSAIDs, aminoglycosides, contrast dye, ACE inhibitors), volume status changes, sepsis risk factors, and urinary symptoms suggesting obstruction. Physical examination focuses on jugular venous distension, peripheral edema, skin turgor, mucous membranes, and bladder distension.
KDIGO AKI Staging
| Stage | Serum Creatinine Criteria | Urine Output Criteria | Clinical Action |
|---|---|---|---|
| Stage 1 | ≥0.3 mg/dL rise within 48h OR 1.5–1.9× baseline within 7 days | <0.5 mL/kg/hr for 6–12 hours | Discontinue nephrotoxins, optimize volume status, monitor Cr q12h, urinalysis with microscopy |
| Stage 2 | 2.0–2.9× baseline | <0.5 mL/kg/hr for ≥12 hours | Nephrology consult, renal-dose drug adjustments, consider renal ultrasound, strict I/O |
| Stage 3 | ≥3.0× baseline OR ≥4.0 mg/dL OR initiation of RRT | <0.3 mL/kg/hr for ≥24h OR anuria for ≥12h | ICU transfer if not already, urgent nephrology, evaluate for RRT, continuous hemodynamic monitoring |
Diagnostic Workup
| Test | Rationale / What It Shows | Sensitivity | Specificity |
|---|---|---|---|
| Urine microscopy (sediment) | Muddy brown granular casts = ATN; RBC casts = glomerulonephritis; WBC casts = interstitial nephritis; bland = prerenal | 80–85% | 85–90% |
| Fractional excretion of sodium (FENa) | <1% suggests prerenal; >2% suggests intrinsic ATN. Unreliable with diuretics or CKD | 78% | 84% |
| FE Urea (FEUrea) | <35% favors prerenal even on diuretics; >50% favors intrinsic injury | 85% | 82% |
| Renal ultrasound | Rules out obstructive uropathy (hydronephrosis); assess kidney size (small = chronic); Doppler for renal artery stenosis | 90–98% (obstruction) | 78–85% |
| NGAL (serum/urine) | Early biomarker rising within 2h of tubular injury; >150 ng/mL predicts AKI development 24–48h before creatinine rise | 76% | 82% |
| TIMP-2 × IGFBP7 (NephroCheck) | Cell-cycle arrest markers; ≥0.3 = moderate risk, ≥2.0 = high risk for Stage 2–3 AKI within 12h | 89% | 50% |
Differential Diagnosis
| Condition | Distinguishing Feature | Key Workup |
|---|---|---|
| Prerenal azotemia | BUN:Cr >20:1, FENa <1%, bland sediment, rapid response to volume resuscitation (Cr normalizes within 24–48h) | FENa, FEUrea, fluid challenge response |
| Acute tubular necrosis (ATN) | Muddy brown granular casts, FENa >2%, persistent AKI despite volume repletion, history of ischemia or nephrotoxin | Urine microscopy, urine sodium >40 mEq/L |
| Acute interstitial nephritis | WBC casts, urine eosinophils (>1%), rash + fever + eosinophilia triad (present in only 10–15%), temporal drug exposure | Urine eosinophils, renal biopsy if diagnostic uncertainty |
| Obstructive uropathy | Bilateral hydronephrosis on ultrasound, sudden anuria, pelvic malignancy history, elevated postvoid residual >200 mL | Renal ultrasound, CT without contrast if stone suspected |
| Glomerulonephritis | RBC casts (pathognomonic), dysmorphic RBCs, proteinuria >3 g/day, hypocomplementemia, positive ANCA or anti-GBM | Complement levels, ANCA, anti-GBM, renal biopsy |
| Hepatorenal syndrome | Cirrhosis + ascites, Cr rise with no structural kidney disease, urine Na <10 mEq/L, no response to albumin challenge | Urine sodium, albumin challenge (1 g/kg/day × 2 days) |
Treatment Algorithm
AKI management is primarily supportive, targeting the underlying etiology while preventing further renal injury. The treatment algorithm follows a stepwise approach: optimize perfusion and volume status, eliminate nephrotoxins, manage complications (hyperkalemia, acidosis, volume overload), and determine timing of renal replacement therapy. No pharmacologic agent has demonstrated efficacy in accelerating AKI recovery—low-dose dopamine, fenoldopam, and loop diuretics do not prevent or treat established AKI. Treatment success is measured by creatinine trajectory and urine output trends, not by any single lab value.
All AKI patients require immediate hemodynamic assessment. For volume-depleted patients, administer balanced crystalloids as first-line resuscitation. Avoid normal saline (0.9% NaCl) for large-volume resuscitation due to hyperchloremic acidosis risk. Discontinue ALL nephrotoxins immediately and hold RAAS inhibitors until creatinine stabilizes. Target MAP ≥65 mmHg—use vasopressors if hypotensive despite adequate volume.
Lactated Ringer or Plasmalyte: 1–2 mL/kg/hr IV balanced crystalloid (adjust to urine output and CVP) Grade A
Norepinephrine (if vasopressor needed): Norepinephrine 0.05–0.5 mcg/kg/min IV targeting MAP ≥65 mmHg
Stop: NSAIDs, aminoglycosides, ACEi/ARBs, iodinated contrast, metformin, vancomycin (recheck levels)
Once intrinsic AKI is established, management shifts to preventing and treating metabolic complications while awaiting tubular recovery. Hyperkalemia is the most immediately life-threatening complication. Volume overload requires diuretic therapy but diuretics do NOT improve AKI outcomes or accelerate recovery—they only manage fluid balance. Metabolic acidosis requires bicarbonate only when pH <7.1 or bicarbonate <15 mEq/L with hemodynamic instability.
Hyperkalemia (K+ >5.5 mEq/L): Calcium gluconate 10% 10 mL IV over 2–3 min (cardiac membrane stabilization)
Insulin-glucose shift: Regular insulin 10 units IV + D50W 50 mL IV (shifts K+ 0.5–1.0 mEq/L in 15–30 min)
Volume overload diuresis: Furosemide 40–80 mg IV bolus (double dose q2h if no response, max 200 mg/dose) Grade B
Acidosis correction: Sodium bicarbonate 150 mEq in 1L D5W at 150 mL/hr (for pH <7.1)
Sodium polystyrene sulfonate: Patiromer 8.4 g PO daily OR Sodium zirconium cyclosilicate 10 g PO TID × 48h then 10 g daily
RRT is indicated for life-threatening complications refractory to medical management. The STARRT-AKI trial demonstrated no survival benefit of early RRT initiation (within 12h of Stage 3) compared with a watchful waiting strategy in the absence of absolute indications. Continuous RRT (CRRT) is preferred for hemodynamically unstable ICU patients, while intermittent hemodialysis (IHD) is appropriate for hemodynamically stable patients. KDIGO recommends delivering a minimum effluent dose of 20–25 mL/kg/hr for CRRT.
CRRT (CVVHDF preferred): CRRT effluent dose 25–30 mL/kg/hr (prescribe 25% above target to account for downtime) Grade A
IHD (for stable patients): IHD 3–4 sessions/week, Kt/V ≥1.2 per session, blood flow 200–300 mL/min
Anticoagulation for CRRT: Regional citrate anticoagulation (preferred) OR heparin 500–1000 units/hr IV (target aPTT 45–55s)
Special Populations
| Population | Drug / Consideration | Specific Recommendation |
|---|---|---|
| CKD Baseline | All nephrotoxins | CKD patients develop AKI at lower absolute Cr thresholds; baseline eGFR <30 lowers threshold for nephrology consult and RRT readiness; avoid contrast if eGFR <30 |
| Hepatic Impairment | Hepatorenal syndrome | Child-Pugh C: low threshold for terlipressin + albumin trial; avoid nephrotoxins; Cr unreliable (low muscle mass); use cystatin C for GFR estimation |
| Elderly (≥65) | Volume resuscitation | Cautious fluid dosing (1 mL/kg/hr max) due to reduced cardiac reserve; monitor for pulmonary edema; sarcopenia causes lower baseline Cr (underestimates AKI severity) |
| Pregnancy | Preeclampsia, HELLP | Normal pregnancy Cr is 0.4–0.6 mg/dL; Cr ≥0.9 may represent significant AKI; avoid ACEi/ARBs (teratogenic); magnesium sulfate safe; early OB and nephrology co-management |
| Pediatric | Fluid resuscitation | Bolus 10–20 mL/kg isotonic crystalloid; neonatal AKI defined by Cr not declining postpartum or rising ≥0.3 mg/dL; pRIFLE criteria preferred over adult KDIGO for children |
Drug Interactions
| Drug | Interacting Agent | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Vancomycin | Piperacillin-tazobactam | Synergistic tubular toxicity; competition for OAT secretion increases vancomycin tubular exposure | 40–50% increased AKI risk vs vancomycin + cefepime | Use cefepime or meropenem instead of pip-tazo when combined with vancomycin |
| ACEi/ARBs | NSAIDs + Diuretics | "Triple whammy": NSAID blocks prostaglandin-mediated afferent dilation, diuretic reduces volume, ACEi blocks efferent constriction | Severe prerenal AKI, especially in elderly and CKD patients | Avoid triple combination; hold ACEi/ARB and NSAID in AKI; restart ACEi/ARB after recovery |
| Metformin | Iodinated contrast | Contrast-induced AKI impairs metformin clearance, causing drug accumulation | Life-threatening lactic acidosis (mortality 30–50%) | Hold metformin 48h before and after contrast; resume only when eGFR confirmed ≥30 mL/min |
| Aminoglycosides | Loop diuretics | Diuretic-induced volume depletion increases aminoglycoside tubular concentration; both are ototoxic | Increased nephrotoxicity and ototoxicity risk | Avoid concurrent use; if essential, extend dosing interval, monitor drug levels and Cr daily |
Stepwise approach
Adult acute kidney injury: diagnosis and management
Management starts immediately, alongside the work-up.
Confirm and stage AKI (KDIGO)
- Creatinine up ≥0.3 mg/dL in 48 h or ≥1.5× baseline in 7 days, or urine output <0.5 mL/kg/h for 6 h
- Urgent nephrology: Stage 2–3, suspected GN, possible RRT
Find the cause
- Urine sediment: muddy brown casts = ATN; RBC casts = GN; WBC casts = interstitial nephritis
- FENa <1% or, on diuretics, FEUrea <35% suggests prerenal
- Possible obstruction: ultrasound, catheter; urology if upper-tract or not relieved
Restore perfusion
- Volume-depleted: lactated Ringer's or Plasma-Lyte by default; 0.9% saline in traumatic brain injury
- Hypotensive, no longer fluid-responsive: norepinephrine to MAP ≥65 mmHg, not more fluid
Remove nephrotoxins
- Stop NSAIDs and metformin; hold ACEi/ARBs
- Aminoglycosides only if essential
- Adjust renally cleared drug doses at the first sign of AKI
Treat complications
- Hyperkalemia with ECG changes: IV calcium gluconate first
- K+ >6.0 mEq/L: IV insulin with glucose, then monitor glucose
- Fluid overload, not anuric: loop diuretic; diuretics and low-dose dopamine do not treat AKI
Renal replacement therapy
- Start for refractory hyperkalemia, acidosis or pulmonary edema, or uremic complications
- Hemodynamically unstable or raised ICP: CRRT; otherwise intermittent hemodialysis
Monitoring & Surveillance
Monitoring intensity scales with AKI severity. Stage 1 patients require creatinine checks every 12 hours and strict intake-output documentation, while Stage 3 patients need hourly urine output measurement, continuous hemodynamic monitoring, and electrolyte panels every 4–6 hours. The most critical early indicator of AKI trajectory is the urine output trend within the first 6–12 hours of intervention. After hospital discharge, all AKI survivors require nephrology follow-up within 90 days to assess for CKD transition, as 15–30% develop chronic kidney disease within 2 years.
- Serum creatinine (q6–12h depending on stage)
- Urine output (hourly via Foley catheter)
- Serum potassium (q4–6h if >5.0 mEq/L)
- Serum bicarbonate / venous blood gas
- Fluid balance (strict I/O every shift)
- BMP (Na, K, Cl, HCO3, BUN, Cr, Glucose, Ca)
- Phosphorus and magnesium
- Daily weight (fluid balance proxy)
- Nephrotoxin reconciliation review
- Serum creatinine (verify recovery to baseline)
- Urinalysis with protein-to-creatinine ratio
- Blood pressure check
- Medication reconciliation (reinstate RAAS inhibitors if appropriate)
- eGFR at 3 months (assess CKD transition)
- Urine albumin-to-creatinine ratio (UACR)
- Blood pressure and cardiovascular risk assessment
- Nephrology follow-up at 90 days post-AKI
Response & Safety Parameters
| Parameter | Target / Threshold | Frequency | Action if Abnormal |
|---|---|---|---|
| Serum creatinine | Trending toward baseline; rise >0.3 mg/dL/day = worsening | q6–12h (acute), daily (recovery) | If rising despite intervention → reassess volume status, nephrology consult, consider RRT |
| Urine output | ≥0.5 mL/kg/hr (target); <0.3 mL/kg/hr = critical | Hourly (Foley), q6h shift totals | If <0.5 mL/kg/hr × 6h despite volume → furosemide stress test (1.0–1.5 mg/kg IV); UO <200 mL/2h predicts Stage 3 progression |
| Serum potassium | 3.5–5.0 mEq/L; >6.0 mEq/L with ECG changes = emergent | q4–6h if >5.0 mEq/L | K+ 5.5–6.0 → kayexalate or patiromer; K+ >6.0 + ECG changes → calcium gluconate + insulin/glucose + consider RRT |
| Serum bicarbonate | ≥18 mEq/L; pH ≥7.2 | q6–12h if <20 mEq/L | pH <7.1 or HCO3 <12 → sodium bicarbonate infusion; if refractory → RRT |
| Volume status | Euvolemia (CVP 8–12, no pulmonary edema, no orthostasis) | q shift reassessment | Overloaded → furosemide; hypovolemic → balanced crystalloid bolus; refractory overload → ultrafiltration via RRT |
Clinical Commentary
ICU transfer: Stage 3 AKI with hemodynamic instability (MAP <65 despite vasopressors), refractory hyperkalemia (K+ >6.5 mEq/L with ECG changes not responding to medical therapy), or pulmonary edema requiring emergent ultrafiltration.
Urology consultation: Obstructive AKI requiring percutaneous nephrostomy or ureteral stenting when Foley catheter does not relieve obstruction.
Post-discharge nephrology follow-up: All AKI survivors within 90 days to assess CKD transition (eGFR and UACR); earlier if residual creatinine elevation >25% above pre-AKI baseline at discharge.
- Optimal timing of RRT initiation in non-emergent AKI Stage 3 remains debated despite STARRT-AKI and IDEAL-ICU trials
- Role of novel biomarkers (NGAL, KIM-1, TIMP-2/IGFBP7) in guiding treatment decisions versus prognosis alone is not established
- Whether early reinstatement of RAAS inhibitors post-AKI improves or worsens long-term renal outcomes lacks randomized evidence
Your kidneys have temporarily lost some of their ability to filter waste and excess fluid from your blood. This condition is called acute kidney injury. The medical team is working to identify the cause—which may include dehydration, certain medications, or an infection—and is providing intravenous fluids, stopping medications that may be harmful to the kidneys, and closely monitoring your blood tests and urine output. Most patients recover kidney function within days to weeks, but follow-up blood tests after discharge are important to ensure full recovery. Your doctor may temporarily hold certain blood pressure medications and will advise when it is safe to restart them.
Practice Insights: AKI After STARRT-AKI, SMART, and the Permissive-Hypotension Pivot
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Fear of the creatinine number drives more decisions in AKI than the patient's volume status does, and across dialysis timing, fluid choice and hepatorenal syndrome, the preferred approach has been quietly rewritten by three landmark trials: STARRT-AKI (early-RRT does not help), SMART (balanced crystalloid beats normal saline), and CONFIRM (terlipressin reverses HRS). The biggest practical shift, though, is psychological: clinicians have learned to tolerate creatinine rise after initial resuscitation rather than chasing it with more fluid or earlier dialysis. Doing less in the right patient is now the harder skill than doing more, and that pivot has prevented more harm in the unit than any new drug.
Balanced crystalloid first; normal saline only for hyperkalemia
Since SMART showed reduced renal composite outcomes with balanced crystalloid versus normal saline, lactated Ringer's or Plasma-Lyte has been the default AKI resuscitation fluid. clinicians use normal saline only when serum K+ is greater than 5.5 (LR contains 4 mEq/L K+, though the practical impact is minimal). The hyperchloremic acidosis from large-volume normal saline causes renal vasoconstriction that worsens the very AKI you are trying to reverse. clinicians have not seen the chloride load in NS get the respect it deserves on most floors.
Tolerate creatinine rise after the first 30 mL/kg
The biggest change in experienced practice from STARRT-AKI and from years of watching post-resuscitation fluid harm: once clinicians have given 25-30 mL/kg of balanced crystalloid and the patient is no longer fluid-responsive by PLR or PPV, clinicians stop fluid. Experienced clinicians tolerate a creatinine peak of 3-4 with the patient on stable low-dose vasopressors. Forcing the creatinine down with more crystalloid produces pulmonary edema, gut edema, and worse renal recovery. Roughly 1 in 4 of the historically-fluid-overloaded AKI patients would have done better with vasopressor support and fluid restriction earlier.
POCUS-driven AKI workup at the bedside
clinicians use bedside ultrasound on every ICU AKI patient: renal arterial Resistive Index (RI greater than 0.7 suggests intrinsic injury rather than prerenal); IVC collapsibility for volume status; lung B-lines for occult pulmonary congestion; bladder scan to rule out obstruction in the elderly. POCUS turns a one-hour workup into a 10-minute one and avoids transport-related risk. In experienced hands, RI greater than 0.8 in a post-cardiac-surgery patient on vasopressors predicts non-resolving AKI better than any biomarker seasoned clinicians can send to the lab.
Terlipressin for HRS — finally, an answer
Before terlipressin's FDA approval in September 2022, the HRS-AKI regimen was norepinephrine plus albumin or midodrine-octreotide-albumin — neither of which experienced practitioners felt great about. Terlipressin 0.5-1 mg IV every 4-6 hours plus albumin 25 percent (1 g/kg day 1, then 20-40 g daily) has reversed creatinine in roughly 30-35 percent of the HRS-AKI patients, compared to about 15-17 percent with the older regimens. Monitor for ischemia (cardiac, mesenteric, peripheral) and respiratory failure (about 11 percent rate). Stop at day 4-7 if no improvement.
Anonymized Case: Post-CABG Day 2 Oligo-Anuric Patient with Volume Overload
A man in his late sixties post on-pump CABG day 2 was consulted to the treating clinicians for oliguria (10 mL/hr) and rising creatinine (0.9 baseline to 2.3) despite 4 L of crystalloid given by the surgical team for "fluid responsiveness." On exam he had bibasilar crackles, B-lines on lung POCUS, IVC plethoric and non-collapsing, RI on renal POCUS 0.8, and norepinephrine 0.2 mcg/kg/min. clinicians stopped further fluid administration, started a furosemide infusion at 5 mg/hr titrated to 10 mg/hr for net negative balance, added vasopressin 0.03 U/min for MAP support, and held all renally cleared medications. Cr peaked at 3.4 on day 4, then declined. No RRT was needed. By day 7 he was net 5 L negative, off vasopressors, with eGFR 52. Discharged day 9.
Four Protocol Deviations Experienced Clinicians Now Default To
- Balanced crystalloid (lactated Ringer's or Plasma-Lyte) as the AKI resuscitation fluid; normal saline only if K+ > 5.5. Per SMART trial outcomes, chloride-induced renal vasoconstriction from NS worsens AKI in the same patients you are trying to resuscitate.
- Stop crystalloid after 25-30 mL/kg if PLR, PPV, or IVC collapsibility no longer supports fluid responsiveness — even if hypotensive. Vasopressor support (NE then add vasopressin 0.03 U/min fixed) over additional fluid in this physiology. CVP is not an acceptable fluid-responsiveness marker.
- POCUS workup at the bedside for every ICU AKI consult. Renal RI > 0.7 = intrinsic injury; IVC for volume; lung B-lines for occult pulmonary congestion; bladder scan in elderly to exclude obstruction. POCUS replaces the 1-hour transport-to-imaging workup with a 10-minute bedside answer.
- Terlipressin (0.5-1 mg IV q4-6h) + albumin 25% as first-line for HRS-AKI; abandon early-RRT for non-emergent AKI Stage 3. Skip IV bicarbonate and NAC for contrast-AKI prophylaxis (PRESERVE trial showed no benefit) — isotonic crystalloid prehydration alone is the only intervention with demonstrated efficacy.
Frequently Asked Questions
- Pre-Renal Acute Kidney Injury: Recognition, FENa Workup, and Volume-Responsive Management
- Acute Interstitial Nephritis: Diagnosis and Management
- Acute Pyelonephritis: Diagnosis and Management
- Diabetic Kidney Disease: Diagnosis, Risk Stratification, and Evidence-Based Management
- ANCA-Associated Vasculitis: GPA, MPA, EGPA Diagnosis and Induction Therapy
- Post-Renal AKI from Urinary Tract Obstruction: Recognition, Decompression, and Post-Obstructive Diuresis Management